Ellen Weisberg

Dana-Farber Cancer Institute, USA 0000-0002-5679-9531

Ellen Weisberg has a Ph.D. degree in pharmacology and is presently an Instructor of medicine at Harvard Medical School. Her primary focus has been the screening, characterization, and development of novel small molecule inhibitors targeted against various hematologic malignancies, including chronic myeloid leukemia (CML), acute myeloid leukemia (AML), multiple myeloma, and Philadelphia Chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). Highlights in her research pursuits include (1) identification of the overexpression of Bcr/Abl tyrosine kinase as a mechanism of resistance to the Abl inhibitor imatinib (Glivec, STI571), (2) preclinical characterization and development of the 2nd generation Abl inhibitor, nilotinib (Novartis), which was FDA-approved for imatinib-resistant leukemia, (3) preclinical characterization and development of the broad spectrum FLT3 inhibitor, PKC412 (Novartis), which is presently in phase III clinical trials, (4) preclinical characterization and development of inhibitor of apoptosis (IAP) inhibitors, LCL161, and LBW242 (Novartis); LCL161 is being considered for testing in clinical trials, and (5) elucidation of the mechanism whereby stromal cells protect leukemia against ABL inhibitor- and mutant FLT3 inhibitor-induced cytotoxicity both in vitro and in vivo.

Biography Updated on 14 April 2011

Scholarly Contributions [Data Provided by scopus]

download